Physician profile
Gregory C Chipman
NPI 1457493967
$15,654.92
in general payments reported to CMS, 2019-2025
61 companies · $4,792 in 2025
The $4,792 reported for 2025 was more than what a typical Medical Oncology provider received nationally (typical 2025 total: $1,158).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $479 · 2020: $279 · 2021: $140 · 2022: $1,692 · 2023: $2,640 · 2024: $5,633 · 2025: $4,792.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $8,966 · Consulting Fee: $2,205 · Long Term Medical Supply Or Device Loan: $1,196 · Travel and Lodging: $667 · Education: $30.66.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $8,966.27 |
| Consulting Fee | $2,205.00 |
| Long Term Medical Supply Or Device Loan | $1,196.40 |
| Travel and Lodging | $667.10 |
| Education | $30.66 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Genentech USA, INC. | $3,314.53 | 2022-2025 | Polivy, Phesgo, Perjeta |
| Novartis Pharmaceuticals Corporation | $2,435.41 | 2022-2025 | |
| Daiichi Sankyo INC. | $1,224.78 | 2020-2025 | Enhertu, Datroway, Injectafer |
| Astrazeneca Pharmaceuticals LP | $829.33 | 2022-2025 | Imfinzi, Enhertu, Calquence |
| Pfizer INC. | $782.64 | 2019-2025 | |
| Merck Sharp & Dohme LLC | $671.91 | 2019-2025 | Keytruda, Lynparza, Keytruda Qlex |
| Glaxosmithkline, LLC. | $420.38 | 2022-2025 | Jemperli, Zejula, Ojjaara |
| Emd Serono, INC. | $366.96 | 2023-2025 | Bavencio |
| E.R. Squibb & Sons, L.L.C. | $356.08 | 2022-2025 | Opdivo, Opdualag, Krazati |
| Janssen Biotech, INC. | $350.19 | 2023-2025 | Darzalex, Tecvayli, Talvey |
| Celgene Corporation | $341.58 | 2019-2025 | Reblozyl, Pomalyst, Opdualag |
| Eisai INC. | $330.31 | 2022-2025 | |
| Genzyme Corporation | $325.42 | 2019-2025 | |
| Abbvie INC. | $311.87 | 2022-2025 | |
| Genmab U.S., INC. | $301.70 | 2021-2025 | Tivdak |
Show all 60 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Incyte Corporation | $294.41 | 2022-2025 | Jakafi, Monjuvi, Niktimvo |
| Amgen INC. | $273.65 | 2019-2023 | Vectibix, Nplate, Xgeva |
| Lilly USA, LLC | $248.18 | 2022-2025 | Jaypirca, Verzenio, Retevmo |
| Array Biopharma INC | $198.51 | 2024-2025 | Braftovi, Mektovi, Lorbrena |
| Takeda Pharmaceuticals U.S.A., INC. | $178.16 | 2023-2025 | Fruzaqla, Ninlaro, Alunbrig |
| Bayer Healthcare Pharmaceuticals INC. | $147.93 | 2019-2025 | |
| Pharmacyclics LLC, An Abbvie Company | $138.60 | 2022-2023 | Imbruvica |
| Rigel Pharmaceuticals, INC. | $111.38 | 2020 | |
| Puma Biotechnology, INC. | $106.58 | 2022-2025 | |
| Karyopharm Therapeutics INC. | $95.85 | 2022-2023 | Xpovio |
| Tersera Therapeutics LLC | $91.49 | 2022-2025 | Zoladex |
| Beigene USA, INC. | $87.08 | 2024-2025 | Brukinsa, Tevimbra |
| Stemline Therapeutics INC. | $83.60 | 2023-2025 | Orserdu |
| Jazz Pharmaceuticals INC. | $82.67 | 2025 | |
| Gilead Sciences, INC. | $75.46 | 2021-2023 | |
| Recordati_rare_diseases_inc. | $71.83 | 2023-2025 | Enjaymo, Sylvant |
| Pharmaessentia USA Corporation | $63.35 | 2023 | Besremi |
| Regeneron Healthcare Solutions, INC. | $60.07 | 2023-2024 | Libtayo |
| Astellas Pharma US INC | $59.18 | 2023-2024 | Xtandi, Cresemba, Ambisome |
| Coherus Oncology, INC. | $58.37 | 2021-2023 | |
| Fennec Pharmaceuticals, INC. | $54.98 | 2024-2025 | Fyarro, Pedmark |
| Kyowa Kirin, INC. | $54.46 | 2019 | |
| Deciphera Pharmaceuticals INC. | $54.45 | 2022-2025 | Qinlock, Romvimza |
| Seagen INC. | $54.37 | 2022-2023 | Tukysa |
| Foundation Medicine, INC. | $51.42 | 2019 | |
| Sumitomo Pharma America, INC. | $48.12 | 2023-2025 | Orgovyx |
| Aveo Pharmaceuticals, INC. | $38.11 | 2023 | Fotivda |
| Ipsen Biopharmaceuticals, INC | $38.05 | 2022-2023 | Tazverik |
| Morphosys, US INC. | $35.69 | 2023 | Monjuvi |
| Exelixis INC. | $32.54 | 2025 | Cabometyx |
| Beone Medicines USA, INC. | $29.67 | 2025 | Brukinsa |
| Immunocore Limited | $27.71 | 2025 | Kimmtrak |
| Pharming Healthcare, INC. | $26.79 | 2024 | Ruconest |
| Immunogen, INC. | $24.93 | 2023 | Elahere |
| Iovance Biotherapeutics, INC. | $24.88 | 2025 | Amtagvi |
| Innate Pharma, INC | $21.31 | 2020 | |
| Legend Biotech USA INC. | $21.14 | 2025 | Carvykti |
| Azurity Pharmaceuticals, INC. | $20.27 | 2025 | Danziten |
| Springworks Therapeutics, INC. | $17.06 | 2024 | Ogsiveo |
| Agios Pharmaceuticals, INC. | $16.32 | 2023 | Pyrukynd |
| Mylan Institutional INC. | $16.19 | 2023 | Fulphila |
| G1 Therapeutics, INC. | $15.83 | 2022 | |
| Cti Biopharma Corp. | $15.71 | 2023 | Vonjo |
| Janssen Pharmaceuticals, INC | $15.30 | 2020 | |
| Clovis Oncology, INC. | $10.18 | 2019 |
1 company reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
Research and ownership
$42,970.82 in ownership or investment interests, as reported to CMS. These are holdings a clinician or an immediate family member has in a company, not payments received.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Gregory Chipman listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.